Minutia

Executive Summary

Minutia is a next-generation cell therapy company developing a novel transplant solution for diabetes. Its core technology integrates insulin-producing cells with nanosensors, enabling real-time, in vivo monitoring of transplanted cell function. This approach addresses a key limitation of current cell therapies—the inability to non-invasively assess graft viability and function over time. By providing continuous feedback, Minutia's platform could improve therapeutic control and patient outcomes. Founded in 2019 and headquartered in San Francisco, the company is privately held and operates in the cell and gene therapy space.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement60% success
• Q4 2026Preclinical Data Presentation at Major Conference80% success
• Q1 2028IND Submission for Lead Candidate40% success